Literature DB >> 1584176

Epidemiology of Parkinson's disease.

C M Tanner1.   

Abstract

Additional epidemiologic studies may provide important insights into the etiology of Parkinson's disease. Moreover as the elderly population of Europe and the United States grows, accurate public health planning requires accurate incidence and prevalence estimates. The recent development of a therapy that may slow disease progression (see article by Tetrud elsewhere in this issue) makes early identification and treatment of Parkinson's disease particularly important. Investigations of early markers of Parkinson's disease or markers of disease susceptibility are critical areas of future research, requiring careful collaboration between epidemiologists and laboratory scientists.

Entities:  

Mesh:

Year:  1992        PMID: 1584176      PMCID: PMC7172502     

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  54 in total

1.  Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

Authors:  M B Spina; G Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Epidemiology of Parkinson's disease in Benghazi, North-East Libya.

Authors:  P P Ashok; K Radhakrishnan; R Sridharan; M E Mousa
Journal:  Clin Neurol Neurosurg       Date:  1986       Impact factor: 1.876

3.  Prevalence of Parkinson's disease in the Republic of San Marino.

Authors:  R D'Alessandro; G Gamberini; E Granieri; G Benassi; S Naccarato; D Manzaroli
Journal:  Neurology       Date:  1987-10       Impact factor: 9.910

4.  Parkinson's disease in a nationwide twin cohort.

Authors:  R J Marttila; J Kaprio; M Koskenvuo; U K Rinne
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

5.  Parkinson's disease. Genetic analysis and evidence of a multifactorial etiology.

Authors:  K Kondo; L T Kurland; W J Schull
Journal:  Mayo Clin Proc       Date:  1973-07       Impact factor: 7.616

6.  Parkinson's disease. A genetic study.

Authors:  W E Martin; W I Young; V E Anderson
Journal:  Brain       Date:  1973-09       Impact factor: 13.501

7.  Environmental risk factors in Parkinson's disease.

Authors:  W Koller; B Vetere-Overfield; C Gray; C Alexander; T Chin; J Dolezal; R Hassanein; C Tanner
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

8.  A large kindred with autosomal dominant Parkinson's disease.

Authors:  L I Golbe; G Di Iorio; V Bonavita; D C Miller; R C Duvoisin
Journal:  Ann Neurol       Date:  1990-03       Impact factor: 10.422

9.  Follow-up study of early-life protective and risk factors in Parkinson's disease.

Authors:  L I Golbe; T M Farrell; P H Davis
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

10.  New data on the genetics of Parkinson's disease.

Authors:  A Barbeau; E Pourcher
Journal:  Can J Neurol Sci       Date:  1982-02       Impact factor: 2.104

View more
  22 in total

Review 1.  Neurodegeneration: what is it and where are we?

Authors:  Serge Przedborski; Miquel Vila; Vernice Jackson-Lewis
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

2.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

Review 3.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

4.  Trichloroethylene and Parkinson's Disease: Risk Assessment.

Authors:  Mei Liu; Eun-Joo Shin; Duy-Khanh Dang; Chun-Hui Jin; Phil Ho Lee; Ji Hoon Jeong; Seok-Joo Park; Yong-Sun Kim; Bin Xing; Tao Xin; Guoying Bing; Hyoung-Chun Kim
Journal:  Mol Neurobiol       Date:  2017-12-22       Impact factor: 5.590

Review 5.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 6.  Ethics of fetal tissue transplantation.

Authors:  L M Sanders; L Giudice; T A Raffin
Journal:  West J Med       Date:  1993-09

Review 7.  Astrocytes and therapeutics for Parkinson's disease.

Authors:  Phillip M Rappold; Kim Tieu
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 8.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

Review 9.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

10.  Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Authors:  Cynthia S Palmer; Mark J C Nuijten; Jordana K Schmier; Prasun Subedi; Edward H Snyder
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.